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ABSTRACT: The isolation of two diarylnonanoids from Dioscorea cotinifolia possessing 
antibiotic-potentiating activity against resistant strains of S. aureus are reported. The 
diarylnonanoids are a class of natural products similar in structure to the diarylheptanoids, 
which have a wide spectrum of reported biological activities. One of the diarylnonanoids 
(1) isolated possesses a chiral center and to deduce its configuration, the modified Mosher 
ester method was used. Using both 1D and 2D NMR data, as many protons as possible 
were assigned to both the R- and S-MTPA esters, and the configuration of the chiral center 
in 1 was determined to be R. Both the chiral and achiral diarylnonanoid (2) exhibited potent 
antibiotic-potentiating activity with the chiral natural product showing a greater 
tetracycline-potentiating activity than 2. Interestingly, 2 gave a higher norfloxacin-
potentiating activity with a resultant higher efflux pump inhibitory activity. Manipulation 






The genus Dioscorea, commonly known as the “yam” taxon, is very well known for its 
phytochemical diversity. The rhizomes of some species are used as both food and medicine 
in many parts of the world. Medicinally, the genus is used in the treatment of wounds, 
sores,1 rheumatism and skin problems.2 Studies on the pharmacological properties of this 
genus have shown anti-inflammatory, analgesic,3 antifungal,1 antitumor4 and anthelmintic 
properties.5 One of the most useful phytochemicals isolated from the family Dioscoreaceae 
is diosgenin, which has an important role in the pharmaceutical industry as the precursor 
for pharmacologically important steroids. Other phytochemicals that have been reported in 
the family include glycosides, flavonoids, alkaloids, phenols, tannins, triterpenoids6 and 
the diarylheptanoids.7 In this study reported are two new diarylnonanoids, an ω-hydroxy 
fatty acid ester from Dioscorea cotinifolia Kunth as well as a bibenzyl from D. sylvatica 
Eckl. var. sylvatica with antibiotic-potentiating activity against methicillin-resistant 
Staphylococcus aureus (MRSA). The potential of these compounds to inhibit 
staphylococcal efflux pumps, which are known be involved in antibiotic resistance, were 
further investigated.  
The diarylnonanoids were isolated from the chloroform extract of the rhizomes of D. 
cotinifolia. Compound 1 was isolated as a yellow solid while compound 2 was isolated as 
a yellow amorphous powder. The IR absorption spectra of both compounds showed a C=O 
bond stretch at 1650 cm-1 and an O-H bond stretch at 3300 cm-1. Using their 1H NMR and 
HRESIMS data, both compounds were identified as 5-hydroxy-1,9-nonane-3,7-diones 
with different substituents at positions 1 and 9. 
The HRESIMS data of compound 1 showed a sodium adduct ion peak [M + Na]+ at m/z 
409.1623, corresponding to the pseudomolecular formula, C22H26O6Na




10 degrees of unsaturation). The 1H NMR data (500 MHz, C6D6) revealed the presence of 
two aromatic ring systems (Table 1). A 1,3,4-trisubstituted aromatic ring system with three 
aromatic resonances, δH 6.46 (1H, d, J = 2.0 Hz), δH 6.99 (1H, d, J = 8.0 Hz) and δH 6.54 
(1H, dd, J = 2.0, 8.0 Hz) accounting for the 4-hydroxy-3- methoxyphenyl moiety of the 
structure (ring A). For the second ring (B), a 1,4-disustituted aromatic ring (AA′BB′) 
system showed two aromatic resonances, each integrating for two protons at δH 6.85 (2H, 
d, J = 8.5 Hz) and δH 6.49 (2H, d, J = 8.5 Hz), and therefore suggesting a 4-hydroxyphenyl 
moiety. A number of key features in the spectroscopic data led to the unambiguous 







Table 1. 1H and 13C NMR Spectroscopic Data and HMBC correlations of 1 and 2a  
no. 
1 2 HMBC 
δC, type δH (J in Hz) δC, type δH (J in Hz)  
1 29.4, CH2 2.73, t (7.5) 29.9, CH2 2.73, t (7.5) 3, 2, 2′, 6′, 1′ 
2 45.8, CH2 2.29 t (7.5) 45.8, CH2 2.29, t (7.5) 1′, 1, 3 
3 209.2, C  209.3, C  1, 5, 2, 4 
4 
49.0, CH2 
2.15, dd (7.8, 4.4) 
2.08, dd (7.8, 4.4) 
49.1, CH2 2.16, dd (7.8, 4.3) 
2.08, dd (7.8, 4.3) 
6, 3, 5 
5 64.9, CH 4.39, m 64.9, CH 4.42, m 3, 7, 4, 6 
6 
49.1, CH2 
2.12, dd (7.8, 4.4) 
2.04, dd (7.8, 4.4) 
49.1, CH2 2.16, dd (7.8, 4.3) 
2.08, dd (7.8, 4.3) 
4, 5, 7 
7 209.3, C  209.3, C  5, 9, 6, 8 
8 45.6, CH2 2.22, t (7.5) 45.8, CH2 2.29, t (7.5) 1″, 7, 9 
9 29.3, CH2 2.68, td (7.5, 2.5) 29.9, CH2 2.73, t (7.5) 7, 2″, 6″, 1″, 8 
1′ 133.4, C  133.3, C  5′, 2, 1, 2′ 
2′ 
111.7, CH 
6.46, d (2.0) 111.8, CH 6.46, d (1.5) 1′, 3′, 4′, 6′, 
OCH3 – 3′ 
3′ 147.2, C  147.2, C   
4′ 145.2, C  145.2, C   
5′ 115.2, CH 6.99, d (8.0) 115.2, CH 6.99, d (8.0) 3′, 1′, 4′ 
6′ 121.6, CH 6.54, dd (8.0, 2.0) 121.6, CH 6.54, dd (8.0, 1.5) 4′, 2′ 
1″ 133.4, C  133.3, C   
2″ 130.1, CH 6.85, d (8.5) 111.8, CH 6.46, d (1.5)  
3″ 115.9, CH 6.49, d (8.5) 147.2, C   
4″ 155.1, C  145.2, C   
5″ 115.9, CH 6.49, d (8.5) 115.2, CH 6.99, d (8.0)  
6″ 130.1, CH 6.85, d (8.5) 121.6, CH 6.5, dd (8.0, 1.5)  




OCH3 – 3″   55.7, CH3 3.21, s 3″ 
OH – 5  3.34, brd    
OH – 4′  5.36, s    
OH – 4″  3.90, brd    
a 500 MHz for 1H and 125 MHz for 13C, recorded in C6D6. 
 
 
Two sets of benzylic protons, δH 2.73 (2H, t, J = 7.5 Hz) and δH 2.68 (2H, dt, J = 7.5 
Hz), were apparent along with a pair of deshielded methylene groups (H2-2 and H2-8) at 
δH 2.29 (2H, t, J = 7.5 Hz) and δH 2.22 (2H, t, J = 7.5 Hz), which showed J correlations 
with C-1 and C-9, respectively, in the HMBC spectrum. Additionally, H2-2 and H2-8 also 
showed J correlations with the carbonyl resonances at C-3 and C-7. Furthermore, two 
deshielded methylene groups with resonances at δH 2.15, 2.08 (2H, dd, J = 7.8, 4.4 Hz, H2-
4) and δH 2.12, 2.04 (2H, dd, J = 7.8, 4.4 Hz, H2-6) exhibited J correlations with an 
oxymethine carbon at C-5. A methoxy group resonance on the aromatic ring A at δH 3.20 
(3H, s), further supported the inference of a 5-hydroxy-1,9-nonane-3,7-dione moiety of 1. 
Further resonances at δH 3.34 (1H, brd), 5.36 (1H, s) and 3.90 (1H, brd), could be attributed 
to the three hydroxy groups at C-5, C-4′ and C-4″, respectively. 
 
The 13C NMR spectrum of 1 revealed 22 carbon resonances with seven quaternary 
carbons missing in the DEPT-135 spectrum, which supported the proposed structure. There 
were two carbonyl resonances (δC 209.2 and 209.3), an oxymethine (δC 64.9) and 
methylenes with different chemical shifts, depending on their proximity to the deshielding 
oxymethine and carbonyl groups (Table 1). In the HMBC spectrum, the proton at position 




correlations with C-8 and C-1″, while the methylene protons at H-1 showed correlations 
with C-2 and C-1′, which enabled the structure of the compound to be confirmed as 5-
hydroxy-1-(4-hydroxy-3-methoxyphenyl)-9-(4-hydroxyphenyl)nonane-3,7-dione. 
The HRESIMS of 2 showed a sodium adduct ion peak [M + Na]+ peak at m/z 439.1729, 
corresponding to a pseudomolecular formula, C23H28O7Na
+ (calcd 439.1733; 10 degrees 
of unsaturation). This was 30 atomic mass units greater than the sodium adduct ion peak 
observed for 1, accounting for the addition of an oxymethylene (OCH2) moiety. The 
1H 
NMR spectrum (500 MHz, C6D6) of 2 was highly similar to that of 1 and revealed the 
absence of a di-substituted aromatic ring (Table 1).  The integrals of the resonances in the 
1,3,4-tri-substituted aromatic ring were doubled, showing two identical aromatic rings, for 
which the protons were equivalent. This observation, and the fact that the integrals of the 
methylenes in the 5-hydroxy-1,9-nonane-3,7-dione moiety were also doubled, led to the 
conclusion that the structure of 2 possesses symmetry and this could be readily explained 
by the proposal of 2 as 5-hydroxy-1,9-bis(4-hydroxy-3-methoxyphenyl)nonane-3,7-dione. 
However, due the exchangeable nature of the hydroxy group protons, they could not be 
detected in the 1H NMR spectrum of 2 in C6D6.  
The 13C NMR spectrum of 2 revealed only 13 carbon signals, which again was consistent 
with the observation of a plane of symmetry at position C-5. The HMBC and COSY data 
were also highly similar to those of 1. To verify if compound 1 was not obtained as an 
artefact, it was isolated from its fraction using preparative TLC with chloroform-acetone-
acetic acid (6:4:0.1). Both compounds were isolated with different retention factors, Rf 
0.34 for 1 and Rf 0.39 for 2.  It was further hypothesized that if 1 was indeed an artefact, 




this was not the case. It was concluded that both compounds are natural products that exist 
in the plant. 
This is the first report of the isolation of diarylnonanoids from the Dioscorea genus. 
Although the diarylheptanoids are similar in structure, and have been previously isolated 
from the Dioscoreaceae family,7–10 diarylnonanoids have a 9-carbon chain linking the two 
aromatic systems. Structurally similar compounds have been isolated from the Myristica 
genus in the plant family Myristicaceae.11–14 Mosher ester analysis was used to deduce the 
absolute configuration of the chiral center (C-5) in compound 1. The Mosher esters, 
obtained by reacting 1 with both (3R)- and (3S)-MTPA chloride to yield the (4S)- and (4R)-
MTPA ester, respectively, were analyzed using both 1D and 2D NMR spectroscopy. The 
data were used to assign as many protons as possible on both the (R)- and (S)-esters. Since 
the methylene protons at positions 2 and 8, as well as those in 4 and 6 were overlapped and 
difficult to distinguish, the benzylic protons at positions 1 and 9, as well as the aromatic 
protons were used for the analysis. HMQC, HMBC and COSY spectra were key in the 
assignments. According to the Kakiswa group,15 the absolute values of ∆δ must be 
proportional quantitatively to the distance from the MTPA moiety. This condition was met, 
bringing confidence to the assignment of the hydrogens of the MTPA esters. Using their 
method, which was later reiterated by Hoye and co-workers,16 the difference in the 
chemical shift (∆δSR) was calculated from each of the analogous pairs of protons for both 











Figure 1. ∆δSR values (bold) for the MTPA ester of 1 (left) and the model used to determine 
the absolute configuration (right). 
 
To determine the absolute configuration, all positive ∆δSR values were assigned to the 
right side of the model (R1) in Figure 1 and all the negative ∆δ
SR values were placed on the 
left (R2) (as per the advanced or modified Mosher ester analysis.
15 By applying the Cahn 
Ingold Prelog system, the priority of the groups on the original carbinol were assigned as; 
1 (OH), 2 (R1), 3 (R2) and 4 (H) and the absolute configuration of the carbinol at C-5 of 1 
was determined as (R). The name was then assigned as (5R)-hydroxy-1-(4-hydroxy-3-
methoxyphenyl)-9-(4-hydroxyphenyl)nonane-3,7-dione. The specific optical rotation was 
determined to be [α]D
20+130.9 (c 0.08, CHCl3).  
The known compounds  (E)-32-((3-(3-hydroxy-4-
methoxyphenyl)isoferuloyl)oxy)dotriacontanoic acid (3)17 and 5-(2-hydroxyphenethyl)-
2,3-dimethoxyphenol) (4)17,18 were isolated from the chloroform extracts of D. cotinifolia 
and D. sylvatica var. sylvatica, respectively.   
The antibiotic-potentiating activities of compounds 1–4 were determined using two 
MDR S. aureus strains possessing characterized efflux proteins namely, SA-1199B, which 




XU212, which is tetracycline-resistant due to the TetK efflux protein.20 S. aureus XU212 
is also resistant to most -lactams due to PBP2a production conferred by the mecA gene.20 
None of the compounds showed inhibitory activity against the S. aureus strains, giving 
minimum inhibitory concentration (MIC) values at >128 mg/L. At sub-inhibitory 
concentrations (1/4 or less of the MIC), the compounds caused a 2- or higher-fold reduction 
in the MIC of the antibiotics when tested against the corresponding resistant strain. 
Compound 1 was the most active, resulting in a 512-fold reduction in the MIC of 
tetracycline against the tetracycline-resistant XU212 strain (Table 2). The ω-hydroxy fatty 
acid ester (3) was also very active and resulted in an 8- and 16-fold reduction in the MIC 
of norfloxacin and tetracycline, respectively. 
The possible effect of the isolated compounds to inhibit the active efflux of an antibiotic 
from cells was investigated using an ethidium bromide accumulation assay. Figure S1 
(Supporting Information) and Table S1 (Supporting Information) show the effects of the 
compounds on the intracellular accumulation of ethidium bromide over time within S. 
aureus SA-1199B. Reserpine, a known efflux pump inhibitor, showed an increase in 
intracellular accumulation of ethidium bromide with a resultant increase in fluorescence 
over a 30-minute period of observation. This activity was dose-dependent and at the 
highest concentration (1/4 MIC), the difference in accumulation (the slope of 2.88) 
compared to that of the control in the absence of the inhibitor (referred to as the “blank”) 
was the highest obtained (Table 2).  Compounds 2 and 4 showed significant efflux pump 
inhibitory (EPI) activity, with slope differences of 2.45 and 2.68, respectively.  
Furthermore, their relative final fluorescence (RFF) was similar to that of reserpine. These 




compounds is due to their EPI activity. 1 gave a lower norfloxacin-potentiating activity 
which corresponded to its weaker efflux pump activity compared to 2.  This was interesting 
because, structurally these two compounds are very similar with only differences in the 
substitution in the second aromatic ring. 
 
Table 2. Antibiotic-Potentiating Activity of Compounds 1–4 
compound 
(sub-inhibitory 
concentration in mg/L) 
MIC (mg/L) of test sample in combination with specified 
antibiotic (fold reduction) against: 
S. aureus 1199B (NorA) 
norfloxacin @ 32 mg/L 
S. aureus XU212 (TetK) 
tetracycline @ 128 mg/L 
1 (100) 16 (2) <0.25 (>512) 
2 (30) 8 (4) 128 
3 (100) 4 (8) 8 (16) 
4 (64) 2 (16) 64 (2) 
reserpine a (20) 16 (2) 64 (2) 
 a Positive control substance 
 
 
From an observation of the structures of the NorA pump inhibitors isolated in this study, 
it seems plausible to suggest that the presence of more than one methoxy groups as well as 
at least two phenyl rings is essential for greater EPI activity. This corroborates with the 
structures of reserpine and verapamil, well known EPIs, which also possess these structural 
characteristics. Kaatz and colleagues21 noted that due to the heterogeneity of reported EPIs, 
it becomes difficult to characterize the critical structure of an “ideal” NorA inhibitor. 
However their recent work on ligand-based pharmacophore modeling suggests that the 




(2) a positive charge, (3) two aromatic rings, and (4) a hydrophobic region.22 Although the 
isolated compounds lacked a positive charge, they possess all the other pharmacophores 
required and therefore displayed NorA inhibitory properties. The bibenzyl 4 also showed 




General Experimental Procedures. The optical rotation of the chiral compound was 
measured on a PolAAR 21 instrument (Optical Activity Ltd) using an A2 series polarimeter 
sample tube with a 100 mm path length. UV-vis absorption spectra were measured on a 
UV-vis (Spectronic Helios Gamma UV-visible spectrophotometer) and IR spectra were 
measured on a Perkin Elmer 100 FT-IR spectrometer. 1D 1H, 13C and DEPT-135, and 2D 
HMQC, HMBC, COSY and NOESY NMR spectroscopic data were acquired on a Bruker 
Avance 500 MHz NMR spectrometer. Deuterated solvents and NMR tubes were purchased 
from Cambridge Isotope Laboratories and Sigma-Aldrich, respectively. Bruker 
TopspinTM, version 3.2 software was used to process NMR data. Low-resolution mass 
spectra were acquired on a LCQ Duo Ion-Trap mass spectrometer (Thermo Fisher 
Scientific), and a Waters Q-TOF Premier Tandem mass spectrometer was used for high-
resolution mass spectrometry. Column chromatography was performed on silica gel 60 
(0.04 – 0.063 mm; Merck) and TLC on Silica gel 60 F254 (Merck) plates. Vanillin-
sulphuric acid and p-anisaldehyde reagents were used to visualize the TLC plates. All 
chemicals used were HPLC grade. Chemicals were supplied by either Sigma-Aldrich or 




Plant Material. Dioscorea cotinifolia (voucher number GM218) and Dioscorea 
sylvatica var. sylvatica (voucher number GM217) were collected in March 2014 from 
Malutha in the south eastern part of Eswatini, Southern Africa. Their exact location was 
recorded with a Global Position System. Botanical identification was done by Mr. M.N. 
Dludlu (Botanist; Eswatini Institute for Research in Traditional Medicine, Medicinal and 
Indigenous Food Plants, University of Eswatini) and voucher specimens were deposited 
with the Eswatini National Herbarium, Malkerns Research Station, Eswatini.  
Extraction and Isolation. The dried and ground rhizomes of D. cotinifolia (544 g) were 
extracted exhaustively in a Soxhlet extractor using hexane, chloroform and methanol to 
yield 0.08%, 0.3% and 0.9%, respectively, of the crude extracts. The chloroform extract 
was biologically active in the preliminary tests and therefore subjected to normal-phase 
SPE with hexane (100%) and subsequently 10% increments of ethyl acetate to yield 11 
fractions. After TLC and 1H NMR analysis, fractions 7, 8, 10 and 11 were targeted for the 
isolation of compounds. Compound 1 (2.5 mg) was isolated from fraction 8 after 
preparative TLC on silica gel with chloroform-acetone-acetic acid (8:2:0.1). Compound 2 
(6.5 mg) was isolated from a combination of fractions 10 and 11 by preparative TLC on 
silica gel using chloroform-acetone-acetic acid (9:1:0.1), and compound 3 (14.8 mg) was 
isolated from fraction 7 which was further purified by column chromatography on silica 
gel using ethyl acetate-hexane (8:2).  
The rhizomes of D. sylvatica var. sylvatica also were successively extracted on an 
ultrasonic bath with hexane, chloroform and methanol. Fractionation of the chloroform 
extract by VLC on silica gel led to fraction 6 (227 mg), eluted with hexane-ethyl acetate 




ether (40-60 oC)-ethyl acetate-formic acid (50:50:1) as mobile phases to yield 75 fractions. 
On the basis of their TLC profile, fractions 10-19 were pooled and further purified by 
preparative TLC to yield compound 4 (20 mg). 
(5R)-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)-9-(4-hydroxyphenyl)nonane-3,7-dione 
(1): yellow solid; [α]D
20 +130.9 (c 0.08, CHCl3); UV (CH3CN) λmax (log Ɛ) 223 (4.38), 279 
(3.91) nm; IR (film) νmax 3296, 2949, 2837, 2141, 1646, 1450 cm
-1; 1H (500 MHz) and 13C 
NMR (125 MHz, C6D6), see Table 1; HRQTOFESIMS m/z 409.1623 [M + Na]
+ (calcd for 
C22H26O6Na
+, 409.16727).  
5-Hydroxy-1,9-bis(4-hydroxy-3-methoxyphenyl)nonane-3,7-dione (2): yellow 
amorphous solid; UV (CH3CN) λmax (log Ɛ) 201 (4.80), 225 (4.20), 280 (3.85); IR (film) 
νmax 3335, 2950, 2837, 1652, 1450 cm
-1; 1H (500 MHz) and 13C NMR (125 MHz, C6D6), 
see Table 1; HRQTOFESIMS m/z 439.1729 [M + Na]+ (calcd for C23H28O7Na
+, 439.1733).  
Preparation of Mosher’s Esters for Spectroscopic Determination of 
Stereochemistry. Mosher’s esters were prepared and analyzed as previously 
described.15,16,23,24 Briefly, compound 1 (500 µg) was dissolved in CDCl3 (600 µL) and dry 
pyridine-d5 (6 µL). Thereafter, either (S)- (+) or (R)-(-)-MTPA-Cl (6 µL; Sigma-Aldrich) 
was added to the reaction mixture and allowed to stand for 24 hours in a desiccator. When 
the reaction was complete the mixture was transferred into an NMR tube and run on a 
Bruker Avance 500 MHz spectrometer to acquire both 1D and 2D NMR data.  
 
Broth Dilution Assay for Determining the Bacterial Minimum Inhibitory 
Concentration (MIC). Minimum inhibitory concentrations were determined by the broth 




Antibiotic-potentiating Activity. Potentiation of antibiotic activity by the test 
compounds used a modulation assay adapted from Dickson and co-workers.28 S. aureus 
strains possessing genes that code for antibiotic resistance against particular antibiotics 
were used for the experiment; a tetracycline-resistant XU212 strain and the norfloxacin-
resistant SA-1199B strain. A sub-inhibitory concentration (X = 1/4 MIC or less) of the 
compound was used for the experiment.  
Real-time Ethidium Bromide Accumulation Assay. The efflux pump inhibition 
activity of the compounds was assessed using real-time analysis of ethidium bromide 
(EtBr) accumulation in the effluxing S. aureus SA-1199B strain. EtBr is a substrate for 
various MDR efflux pumps and reversibly binds DNA.21,29 It enters the cell by diffusion 
and is pumped out of effluxing cells via an efflux mechanism. Real-time analysis allows 
for the monitoring of the influx and efflux activity of EtBr within the cell.30 The assay was 
performed as described by Ramalhete and co-workers31 with minor modifications. 
Fluorescence was measured on a BioTek® SynergyTM HT multi-detection plate reader, at 
excitation and emission wavelengths of 535 / 590 for 30 minutes, with readings taken every 
minute. A positive control (reserpine) and a blank (without EPI) were included in the 
experiment. The data was processed using Gen5TM v1.09 software.  
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